Hidradenitis Suppurativa Registry of the Spanish Academy of Dermatology and Venereology (REHS): overview and performance metrics during the initial year.

Abstract

Introduction: Hidradenitis suppurativa (HS) is a skin disease which has a major impact on the patients' quality of life. There are still uncertainties surrounding its epidemiology, natural history and saftety and efficacy profile of existing treatments. The Spanish Academy of Dermatology and Venereology has promoted the creation of a Spanish Registry of patients with HS (REHS). The aim of this article is to present the REHS and give and overview and provide the performance metrics during the initial year.

Methods: The REHS is a prospective, multicenter, observational study that collects the clinical and epidemiological characteristics of patients with HS, and the safety and efficacy profil of the medical and surgical treatments received.

Results: A total of 359 patients were recruited from 23 Spanish centers from June 2023 through June 2024. The patients' mean age was 37 years (53% women). More than 70% of the patients were smokers or ex-smokers. One third had a family history of HS. The most frequent sites of disease onset are the axillae and groin. Median baseline IHS4 at recruitment was 4 (p25-p75=1-9), HiSQOL was 20 (p25-p75=8-36), and BMI was 27.3 (p25-p75=24-33.2). At least, 82% of patients have received antibiotic therapy for their disease, and almost 20% a biologic drug.

Conclusions: We present data from the first patients enrolled in the REHS, which will allow us to generate evidence on the natural course of the disease, and understand the safety and efficacy profile of treatments in HS.